SEC Form 4 · accession 0001562180-18-001025
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rajesh Malik
Officer — Ch. Medical Officer & SVP R&D
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 11:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 2,890 | $0.30 | A | 2,890 | D | |
| Common Stock | Feb 15, 2018 | M | 886 | $0.39 | A | 3,776 | D | |
| Common Stock | Feb 15, 2018 | S | 3,776 | $20.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $0.39 | Feb 15, 2018 | M | 886 | D | — | Dec 5, 2023 | Common Stock | 886 | 3,280 | D |
| Stock Options (Right to Buy)F2 | $0.30 | Feb 15, 2018 | M | 2,890 | D | — | Aug 29, 2023 | Common Stock | 2,890 | 0 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2All shares underlying this option have vested.
Remarks
Exhibit 24.1 - Power of Attorney